Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing… read more.
Professor Philippe Moreau (Nantes, France) and Professor Paul Richardson (Boston, USA) give their opinion on sequencing in myeloma and options at relapse and Dr Rakesh Popat (London, UK) highlights the real life management… read more.
In the ‘Great Debates in MM’ session Professor Paul Richardson (Boston, USA) argued the pros and cons of RVd vs KRd in the frontline. Written by Esther Drain
Many newly diagnosed patients receive multiple myeloma treatment for more than 12 months, according to data collected from treatment centers around the world, showing that the shift away… read more.
Progression-free survival (PFS) and overall survival (OS) were improved similarly with maintenance therapy with lenalidomide or bortezomib in two studies presented at the International Myeloma Workshop. Written by… read more.
Preliminary results from a real-world study show that patients at an older age with a high comorbidity burden had their normal activities uninterrupted when they switched to the… read more.
Professor Kwee Yong (London, UK) details the results from the Tourmaline-MM3 study.
“The genome can be thought of as the hardware driving a cell whereas the epigenome is more like the software – it is dynamic and erasable”, said Professor Ari… read more.
Prof Stephen Ansell (Rochester, USA) discusses how the new cellular technologies are being integrated into standard practice.Written by Esther Drain.
The first CAR T-cell treatment was administered in 2010 but the field has developed rapidly since then and in the first quarter of 2018 more than 100 trials… read more.
Checkmate 205, Cohort D. The results of the two-year, post-treatment follow-up of the Checkmate 205, Cohort D study group suggests that nivolumab followed by nivolumab + AVD could… read more.
Although early stage HL patients have an outstanding result, according to Prof Stephen Ansell (Rochester, USA), he argues that those with stage 3 and 4 disease don’t do nearly as… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
